HISTORY

2025


06Certified as an Excellent Company for Employee Invention Compensation
05Selected for the Next Challenge Global Collaboration Program with Astellas
04

Chosen as a joint research partner for the Ministry of Health and Welfare’s Genome Editing-Based Therapeutics Development Program


2024


12
Innobiz company certification completed
11
Adeno-associated virus mutant patent application
10
Patent registration for high-yield, high-quality recombinant adeno-associated virus production method
08
Selection of Global Industrial Technology Cooperation Center project (joint research institute)
08
Selection of 2024 Seoul-type R&D biomedical technology commercialization support project
07
Patent application for BEST1 gene editing method using CRISPR/Cas system
05
Selection of baby unicorn fostering project
05
Selection of scale-up tips project


2023


10
Series A 5 billion won investment attraction completed
(TS Investment, Shinhan Capital, Smilegate Investment, Wonik Investment Partners)
4
Selected as one of 100 startups in materials, parts, and equipment


2022


12
Completed application for provisional specification of Korean patent for recombinant AAV manufacturing method
09
Expansion of business location
(Addition of 1021 and 1022, B-dong 2, Hanam Hyundai Knowledge Industry Center Hangang Misa)
08
A total of 8 government projects and support projects selected
(Cumulative government and local government support project cost of approximately 6.5 billion won),
Recruitment of first research institute director and strategic planning headquarters director
07
Selection of Gyeonggi-do type smart factory construction support project
07
Ministry of Health and Welfare regenerative medicine clinical research infrastructure establishment project cell gene therapy

Project selected for development of virus materials and production technology for production
(5 years of research and development period, total project cost of 5.4 billion won)


2021


12
Selected for TIPS Startup Commercialization Project (Public-Private Joint Entrepreneur Discovery and Incubation Project),
Selected for Seoul Biohub Entry Permit Company (BT-IT Convergence Center) and Completed Installation of Seoul Branch
11
Venture business certification completed, corporate research institute LMO & Biosafety Level 2 approval completed
10
Konkuk University School of Medicine and Rare and Incurable Disease Pipeline MOU signed for joint research
08
Business location Hanam Hyundai Knowledge Industry Center Moved into 1023 (headquarters), 1014 (laboratory) of B-dong 2, Hangang Misa(including relocation of corporate research institute)
07
2 papers published, technology transfer agreement with Kyungpook National University, Selected as a project for TIPS R&D Startup Growth Technology Development Project
05
Innopolis Partners (Ltd.) Attracts seed investment (headquarters), Establishes corporate research institute


2020


09
Establishment of Aavatar Therapeutics Inc.


Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.


We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.



MON — FRI (8 AM ~ 5 PM)

TEL  |  070-4229-0321

EMAIL  |  information@aavatartps.com




COMPANY  |  AAVATAR Therapeutics

CEO  |  Seunghee Cho

BUSINESS NUMBER  |  235-81-02296


HQ

Unit 1023, Building B, 540 Misa-daero,

Hanam-si, Gyeonggi-do, Republic of Korea


BioHub

Room 203, R&D Center, Seoul Bio Hub, 117-3,

Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea


Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved.

Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.



We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.

MON — FRI (8 AM ~ 5 PM)

TEL  |  070-4229-0321

EMAIL  |  information@aavatartps.com


COMPANY  |  AAVATAR Therapeutics    CEO  |  Seunghee Cho      BUSINESS NUMBER  |  235-81-02296

HQ  |  Unit 1023, Building B, 540 Misa-daero, Hanam-si, Gyeonggi-do, Republic of Korea

BioHub  |  Room 203, R&D Center, Seoul Bio Hub, 117-3, Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea


Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved. |  SITE BY. DOTCLE